Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration Click here to access full article Plain language summary: “Age, sex, smoking status and other common factors may predict which patients with axial spondyloarthritis achieve inactive disease when treated with TNF [...]
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response Click here to access full article
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis Click here to access full article
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries Click here to access full article
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration Click here to access full article
Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis Click here to access full article
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration Click here to access full article
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA Click here to access full article
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration Click here to access full article